Summary & Overview
Cardiac Pacemaker Revision Except Device Replacement with MCC: Inpatient Reimbursement Overview
DRG 260 encompasses inpatient cardiac pacemaker revision procedures except device replacement when a Major Complication or Comorbidity is present, defining the clinical scope and case complexity. This influences inpatient reimbursement because the Major Complication or Comorbidity designation increases the payment weight within the Diagnosis-Related Group system used by Centers for Medicare & Medicaid Services.
DRG 260 Overview
DRG 260 covers inpatient admissions for cardiac pacemaker revision procedures excluding complete device replacement when a Major Complication or Comorbidity is present. This Diagnosis-Related Group applies to cases where the patient requires revision for malfunction, lead issues, erosion, or infection-related procedures short of full system replacement and has significant comorbid conditions that increase resource use. It matters for Medicare payment because the presence of a Major Complication or Comorbidity raises the relative payment weight, impacting hospital reimbursement for the inpatient stay. Accurate clinical coding of the procedure and accompanying Major Complication or Comorbidity is essential to properly classify the admission.
Clinical Trials
- Trials evaluating optimized surgical techniques and perioperative protocols for pacemaker generator or lead revision in patients with complex devices or prior infections. These studies focus on adults admitted for revision procedures who may have lead malfunction, pocket complications, or device-related infection requiring revision with major complications (MCC). Results are relevant to hospitals and payers because improved operative approaches and standardized perioperative care can reduce length of stay, complication rates, and resource use for high-cost inpatient episodes under this DRG.
- Comparative effectiveness studies assessing lead extraction versus targeted revision strategies in high-risk patients with systemic infection or lead failure. These trials enroll older patients with comorbidities (eg, endocarditis, renal disease) to determine which intervention yields better survival, lower readmission, and fewer downstream procedures. Payers and clinicians benefit from evidence on which approach minimizes total cost of care and avoids repeat inpatient admissions for device-related complications.
- Post-discharge outcomes and care coordination research examining rehabilitation, wound surveillance, and remote device monitoring after inpatient pacemaker revision. These prospective cohort or health-services studies follow patients after discharge to measure rehospitalization, device-related adverse events, and outpatient utilization, often stratified by functional status and social support. Findings inform discharge planning, outpatient follow-up intensity, and reimbursement models by identifying strategies that reduce costly readmissions and improve long-term device management.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.